Capitolis Liquid Global Markets’s AstraZeneca AZN Stock Holding History

Capitolis Liquid Global Markets’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,950	Closed	-$1.07M	–	323
2025 Q3	$1.07M	Buy	+6,950	New	+$1.05M	0.01%	227
2025 Q2	–	Sell	-6,950	Closed	-$1.02M	–	252
2025 Q1	$1.02M	Buy	+6,950	New	+$1.01M	0.01%	205
2024 Q3	–	Sell	-29,500	Closed	-$4.6M	–	110
2024 Q2	$4.6M	Buy	+29,500	New	+$4.44M	0.06%	101
2024 Q1	–	Sell	-36,000	Closed	-$4.85M	–	118
2023 Q4	$4.85M	Buy	+36,000	New	+$4.68M	0.2%	71

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capitolis Liquid Global Markets's AZN Position: Q4 2025 in Review

Capitolis Liquid Global Markets sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 6,950 shares — an estimated $1.07M sold.

Capitolis Liquid Global Markets first reported a position in AZN in Q4 2023 and held it in 4 quarters. The position peaked at $4.85M in Q4 2023. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Capitolis Liquid Global Markets reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Capitolis Liquid Global Markets sold 6,950 AstraZeneca shares in Q4 2025, an estimated $1.07M.
Capitolis Liquid Global Markets first reported a position in AstraZeneca in Q4 2023 and held it in 4 quarters.
Capitolis Liquid Global Markets's AstraZeneca position peaked at $4.85M in Q4 2023.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Capitolis Liquid Global Markets's 13F filing for Q4 2025, filed 17 Feb 2026.